drug
ferumoxytol
Marketedupdated 3mo agoby Covis Pharma BV
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying ferumoxytol
- phase3A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
- phase3A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- phase2Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
- phase2Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
- N/ATotal Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
- phase3Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- EP1Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay
- phase2Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 16, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
FDA exclusivities (2)
- Oct 16, 2028NPNP2.2y
- Oct 16, 2028NPNP2.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that